Table 2. Seroprevalence by type of vaccine among healthy individuals and cancer patients .

¹TP1: pre-first dose, TP2: pre-second dose, TP3: 2 weeks post-second dose, TP4: 6 months post-first dose.

²Antibodies considered present if IgG titer was above 0.8 U/ml.

Time point (TP)1	BNT162B2		AZ1222		Coronavac
	Seroprevalence %	N with detectable antibodies2/Total with data	Seroprevalence %	N with detectable antibodies2/Total with data	Seroprevalence %	N with detectable antibodies2/Total with data
Cancer cohort
TP1	15.0	46/307	86.7	13/15	16.7	1/6
TP2	76.3	273/358	100	19/19	16.7	2/12
TP3	95.8	343/358	100	19/19	66.7	8/12
TP4	95.7	223/233	100	18/18	85.7	6/7
Healthy cohort
TP1	6.6	10/151			2.1	2/95
TP2	100	151/151			100	95/95
TP3	100	127/127			100	93/93
TP4	100	52/52			100	83/84